Showing results (161-170 of 219) with videos related to

Sort By:
Pageof 22
Cancer Chemotherapy and Pharmacology|November 4, 2020
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignanciesShigehisa Kitano, Toshio Shimizu, Takafumi Koyama, et al.
Clinical Pharmacology and Therapeutics|March 1, 2020
MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform TrialHitomi S Okuma, Kan Yonemori, Shoko N Narita, et al.
Rinsho Shinkeigaku = Clinical Neurology|March 24, 2024
The clinical practice guideline for the management of amyotrophic lateral sclerosis in Japan-update 2023Makoto Urushitani, Hitoshi Warita, Naoki Atsuta, et al.
Investigational New Drugs|December 5, 2022
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trialsShigemasa Takamizawa, Yuki Katsuya, Yi-Ning Chen, et al.
Japanese Journal of Clinical Oncology|February 23, 2021
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation studyKan Yonemori, Toshio Shimizu, Shunsuke Kondo, et al.
Expert Review of Anticancer Therapy|July 1, 2024
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLCPierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, et al.
Internal Medicine (Tokyo, Japan)|January 18, 2021
Immunoglobulin G4-related Disease Accompanied by Peripheral Neuropathy: A Report of Two CasesTomoya Kawazoe, Tomoyuki Inoue, Shinsuke Tobisawa, et al.
Cancer Medicine|March 31, 2023
FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignanciesYutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, et al.
Investigational New Drugs|May 25, 2019
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumoursTakahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, et al.
Investigational New Drugs|February 9, 2021
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumorsNoboru Yamamoto, Toshio Shimizu, Kan Yonemori, et al.
Pageof 22